{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:10:42Z","timestamp":1775628642575,"version":"3.50.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive impairment, with the \u03b2-amyloid protein (A\u03b2) aggregation as a core pathological driver. As global aging intensifies, AD poses a severe public health burden, highlighting the urgency of developing effective immunotherapies. This review aims to systematically summarize the research progress of A\u03b2-targeted AD vaccines, from first-generation approaches to next-generation strategies, and discuss key challenges and future directions for clinical translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across PubMed, Web of Science, the Cochrane Library, EMBASE, and Google Scholar up to 14 November 2025. Relevant studies were selected using predefined eligibility criteria, focusing on A\u03b2-targeted AD vaccines\u2019 development, mechanisms, preclinical efficacy, and clinical outcomes. Review articles and meta-analyses were included, while case reports and non-A\u03b2-targeted studies were excluded. Data extraction and synthesis focused on vaccine strategies, immune mechanisms, and translational challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>First-generation A\u03b2 vaccine (e.g., AN-1792) showed preclinical promise but failed clinically due to autoimmune complications. Next-generation vaccines, including peptide\/epitope vaccines, DNA vaccines, viral vector vaccines, and protein self-assembling vaccines, have been developed to induce protective Th2-biased immune responses while avoiding harmful T-cell reactions. Preclinical studies demonstrate reduced A\u03b2 deposition and improved cognitive function, with several candidates advancing to clinical trials showing favorable safety and immunogenicity. Key mechanisms include Fc receptor-mediated phagocytosis, antibody-mediated fibril disaggregation, and the peripheral A\u03b2 sink effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A\u03b2-targeted AD vaccines have evolved toward safer and more effective designs, with multiple strategies showing translational potential. Challenges remain, including blood-brain barrier (BBB) penetration, immune response modulation, and defining optimal therapeutic time windows. Future research should focus on personalized vaccines, combination therapies, and novel antigen delivery platforms to fully realize the clinical potential of AD immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fragi.2026.1794820","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:33:23Z","timestamp":1775626403000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on Alzheimer\u2019s disease vaccines: from A\u03b2-targeted approaches to clinical translation"],"prefix":"10.3389","volume":"7","author":[{"given":"Yan","family":"Han","sequence":"first","affiliation":[{"name":"Affiliated Hospital of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaomei","family":"Luo","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhao","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhicheng","family":"Cai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[{"name":"Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Kuang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Nursing, Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"Clinical College of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghuang","family":"Ming","sequence":"additional","affiliation":[{"name":"Clinical College of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"He","sequence":"additional","affiliation":[{"name":"Clinical College of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zimeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical College of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical College of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanchan","family":"Xiao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Jinan University","place":["Guangzhou, Guangdong, China"]},{"name":"Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingbing","family":"Hu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Yan","sequence":"additional","affiliation":[{"name":"Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","article-title":"Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide","volume":"174","author":"Agadjanyan","year":"2005","journal-title":"J. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41593-025-02125-8","article-title":"The Alzheimer's therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia","volume":"29","author":"Albertini","year":"2026","journal-title":"Nat. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/85525","article-title":"Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy","volume":"7","author":"Bacskai","year":"2001","journal-title":"Nat. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/415462a","article-title":"Nerve inflammation halts trial for Alzheimer's drug","volume":"415","author":"Check","year":"2002","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/gt.2009.140","article-title":"DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice","volume":"17","author":"Davtyan","year":"2010","journal-title":"Gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jneumeth.2013.05.006","article-title":"Anti-A\u03b2 antibodies induced by A\u03b2-HBc virus-like particles prevent A\u03b2 aggregation and protect PC12 cells against toxicity of A\u03b21\u201340","volume":"218","author":"Feng","year":"2013","journal-title":"J. Neurosci. Methods"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/S0264-410X(02)00609-6","article-title":"Reduction of \u03b2-amyloid plaques in brain of transgenic mouse model of Alzheimer\u2019s disease by EFRH-phage immunization","volume":"21","author":"Frenkel","year":"2003","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1172\/jci23241","article-title":"Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease","volume":"115","author":"Frenkel","year":"2005","journal-title":"J. Clin. Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1002\/eji.200324000","article-title":"Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene","volume":"33","author":"Ghochikyan","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nm847","article-title":"Alzheimer disease's double-edged vaccine","volume":"9","author":"Greenberg","year":"2003","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3233\/jad-2004-6504","article-title":"Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease","volume":"6","author":"Hara","year":"2004","journal-title":"J. Alzheimers Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/brain\/awt308","article-title":"Sustained peripheral depletion of amyloid-\u03b2 with a novel form of neprilysin does not affect central levels of amyloid-\u03b2","volume":"137","author":"Henderson","year":"2014","journal-title":"Brain"},{"key":"B15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"B16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer's disease","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cdt3.155","article-title":"Translational medicine in Alzheimer's Disease: the journey of donanemab from discovery to clinical application","volume":"11","author":"Jayaprakash","year":"2025","journal-title":"Chronic Dis. Transl. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jconrel.2024.09.012","article-title":"Amyloid-\u03b2-targeting immunotherapies for Alzheimer's disease","volume":"375","author":"Jin","year":"2024","journal-title":"J. Control Release"},{"key":"B20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13195-024-01620-7","article-title":"Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217","volume":"16","author":"Kovacech","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3988\/jcn.2024.0527","article-title":"Monoclonal Antibodies-A new horizon in alzheimer's treatment","volume":"21","author":"Kwon","year":"2025","journal-title":"J. Clin. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1326-8-36","article-title":"Immunotherapy for Alzheimer's disease: hoops and hurdles","volume":"8","author":"Lemere","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"B23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/10445490152717569","article-title":"Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease","volume":"20","author":"Lemere","year":"2001","journal-title":"DNA Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/adr-230025","article-title":"Antibody-mediated clearance of brain Amyloid-\u03b2: Mechanisms of action, effects of natural and monoclonal Anti-A\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s11481-012-9371-2","article-title":"Efficacy of a therapeutic vaccine using mutated \u03b2-amyloid sensitized dendritic cells in Alzheimer's mice","volume":"7","author":"Luo","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1039\/d4bm00173g","article-title":"Fusion of amyloid beta with ferritin yields an isolated oligomeric beta-sheet-rich aggregate inside the ferritin cage","volume":"12","author":"Maity","year":"2024","journal-title":"Biomater. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0115237","DOI":"10.1371\/journal.pone.0115237","article-title":"Tailoring the antibody response to aggregated A\u00df using novel Alzheimer-vaccines","volume":"10","author":"Mandler","year":"2015","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/jci18104","article-title":"Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease","volume":"112","author":"Monsonego","year":"2003","journal-title":"J. Clin. Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1074\/jbc.M609690200","article-title":"Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide","volume":"282","author":"Moretto","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2124","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jneuroim.2008.08.016","article-title":"DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype","volume":"205","author":"Movsesyan","year":"","journal-title":"J. Neuroimmunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1073\/pnas.022627199","article-title":"A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice","volume":"99","author":"Nicolau","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","article-title":"Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome","volume":"43","author":"Oddo","year":"2004","journal-title":"Neuron"},{"key":"B37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4161\/hv.5.6.7815","article-title":"Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination","volume":"5","author":"Okura","year":"2009","journal-title":"Hum. Vaccin"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9619","DOI":"10.1073\/pnas.0600966103","article-title":"Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety","volume":"103","author":"Okura","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.wnl.0000073623.84147.a8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e70776","DOI":"10.1002\/alz.70776","article-title":"Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against A\u03b240 in patients with mild cognitive impairment or very mild Alzheimer's disease: a randomized, double-blind, placebo-controlled phase 2 study","volume":"21","author":"Pascual-Lucas","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B41","doi-asserted-by":"publisher","first-page":"104823","DOI":"10.1016\/j.nbd.2020.104823","article-title":"Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials","volume":"139","author":"Petrushina","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.molimm.2009.05.017","article-title":"Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides","volume":"46","author":"Rossi","year":"2009","journal-title":"Mol. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14283\/jpad.2015.63","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE\u00ae AD02 in patients with early Alzheimer's disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/nrr.Nrr-d-24-00846","article-title":"Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer's disease","volume":"21","author":"Sha","year":"2026","journal-title":"Neural Regen. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/jci10498","article-title":"Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J. Clin. Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e075830","DOI":"10.1002\/alz.075830","article-title":"4. An innovative clinical trial designed to evaluate the effects of ACI-24.060 in Alzheimer\u2019s disease and in Down syndrome (ABATE study)","volume":"19","author":"Sol","year":"2023","journal-title":"Alzheimer's and Dementia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"105940","DOI":"10.1016\/j.ebiom.2025.105940","article-title":"Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study","volume":"120","author":"Sol","year":"2025","journal-title":"EBioMedicine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","article-title":"Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide","volume":"93","author":"Solomon","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"41154","DOI":"10.18632\/oncotarget.17074","article-title":"The antigen-binding fragment of human gamma immunoglobulin prevents amyloid \u03b2-peptide folding into \u03b2-sheet to form oligomers","volume":"8","author":"Valls-Comamala","year":"2017","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14283\/jpad.2016.91","article-title":"Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer's disease: amyloid imaging positron emission tomography and safety results from a phase 2 study","volume":"3","author":"van Dyck","year":"2016","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer's disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.ebiom.2023.104665","article-title":"Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"94","author":"Yu","year":"2023","journal-title":"EBioMedicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e095440","DOI":"10.1002\/alz.095440","article-title":"Phase 1b trial on the safety, tolerability and immunogenicity of anti\u2010amyloid vaccine ALZ\u2010101 in subjects with MCI or mild AD","volume":"20","author":"Zetterberg","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B57","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.nbd.2003.07.005","article-title":"A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease","volume":"14","author":"Zhang","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jns.2008.05.003","article-title":"Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable A\u03b21\u201315 reduces A\u03b2 burden and behavioral impairment without A\u03b2-specific T cell response","volume":"272","author":"Zou","year":"2008","journal-title":"J. Neurological Sci."}],"container-title":["Frontiers in Aging"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2026.1794820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:33:24Z","timestamp":1775626404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2026.1794820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":58,"alternative-id":["10.3389\/fragi.2026.1794820"],"URL":"https:\/\/doi.org\/10.3389\/fragi.2026.1794820","relation":{},"ISSN":["2673-6217"],"issn-type":[{"value":"2673-6217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"1794820"}}